Advertisement
Advertisement

SNGX

SNGX logo

Soligenix, Inc. Common Stock

0.38
USD
Sponsored
-0.01
-3.72%
Aug 10, 15:59 UTC -4
Closed
exchange

After-Market

0.39

+0.01
+2.52%

SNGX Earnings Reports

Positive Surprise Ratio

SNGX beat 24 of 40 last estimates.

60%

Next Report

In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.15
Implied change from Q1 26 (Revenue/ EPS)
--
/
-46.43%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-81.71%

Soligenix, Inc. Common Stock earnings per share and revenue

On May 08, 2026, SNGX reported earnings of -0.28 USD per share (EPS) for Q1 26, beating the estimate of -0.28 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.40% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.15 USD, with revenue projected to reach -- USD, implying an decrease of -46.43% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
logo
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
logo
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
logo
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
logo
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
logo
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
logo
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
logo
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
logo
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
logo
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
For Q1 2026, Soligenix, Inc. Common Stock reported EPS of -$0.28, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.4%, changed from $0.29 before the earnings release to $0.28 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on 3 analysts, Soligenix, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement